UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October, 2015
Commission File Number: 001-37368
ADAPTIMMUNE THERAPEUTICS PLC
(Translation of registrant’s name into English)
101 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
|
Form 20-F |
|
x |
Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
|
Yes |
|
o |
No o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|
Yes |
|
o |
No o |
Other Events
On October 16, 2015, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing that on October 20, 2015, Helen Tayton-Martin, the Company’s Chief Operating Officer, will be presenting at the 2015 BIO Investor Forum and James Noble, the Company’s Chief Executive Officer, will be a featured speaker at that conference. The press release is attached as Exhibit 99.1 and the presentation materials are attached as Exhibit 99.2 hereto and both exhibits are incorporated by reference herein.
Exhibits
|
99.1 Press release dated October 16, 2015 |
|
99.2 Presentation materials dated October 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Adaptimmune Therapeutics plc | |
|
|
|
|
|
|
By: |
/s/ Margaret Henry |
|
|
Name: |
Margaret Henry |
|
|
Title: |
Corporate Secretary |
|
|
|
|
|
Date: October 19, 2015 |
|
|